Drug discovery startup Recursion raises $60 million in Series B from Data Collective 

 Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify 100 new treatments in 10 years. That’s a lofty goal, considering the discovery for just one drug can traditionally take decades and tens of millions of dollars, with a high rate of failure… Read More

Sign in to read full story
In order for you to continue reading the full contents of the post, you will need to login first